Voyager Therapeutics Inc • VYGR

Capital at risk.

About Voyager Therapeutics Inc
Ticker
info
VYGR
Trading on
info
NASDAQ
ISIN
info
US92915B1061
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Headquarters
info
75 Hayden Avenue, Lexington, MA, United States, 02421
Employees
info
141
Website
info
voyagertherapeutics.com
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$239M
P/E ratio
info
-
EPS
info
-$2.04
Dividend Yield
info
0.00%
Beta
info
1.26
Forward P/E ratio
info
8.44
EBIDTA
info
$-124M
Ex dividend date
info
-
Price & volume
Market cap
info
$239M
Average daily volume
info
0.5M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
8.44
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
5.93
Price to book
info
1.19
Earnings
EPS
info
-$2.04
EPS estimate (current quarter)
info
-$0.51
EPS estimate (next quarter)
info
-$0.49
EBITDA
info
$-124M
Revenues (TTM)
info
$40.4M
Revenues per share (TTM)
info
$0.69
Technicals
Beta
info
1.26
52-week High
info
$5.55
52-week Low
info
$2.65
50-day moving average
info
$4.03
200-day moving average
info
$4.04
Short ratio
info
5.45
Short %
info
6.94%
Management effectiveness
ROE (TTM)
info
-48.29%
ROA (TTM)
info
-24.86%
Profit margin
info
-296.53%
Gross profit margin
info
$-91.9M
Operating margin
info
-172.35%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
144.30%
Share stats
Outstanding Shares
info
60.4M
Float
info
39M
Insiders %
info
15.08%
Institutions %
info
59.20%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 12 analysts.

Average price target

info
$14.89
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.53
-$0.44
-20.45%
Q1 • 25Missed
-$0.57
-$0.53
-7.55%
Q2 • 25Missed
-$0.47
-$0.52
9.62%
Q3 • 25Beat
-$0.47
-$0.51
7.93%
Q4 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$15.3M
$-27.4M
-178.83%
Q4 • 25
$2.6M
$-27.9M
-1,077.40%
Q1 • 26
-83.09%
1.86%
502.46%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$252M
$56.2M
22.28%
Q4 • 25
$219M
$45.7M
20.82%
Q1 • 26
-13.06%
-18.76%
-6.55%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-30.3M
$48.1M
$0.1M
$-30.9M
Q4 • 25
$-33.4M
-
$3.3M
$-33.4M
Q1 • 26
10.43%
-
2,350.00%
8.24%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Voyager Therapeutics Inc share?
Collapse

Voyager Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Voyager Therapeutics Inc have?
Collapse

Voyager Therapeutics Inc currently has 60.4M shares.

Does Voyager Therapeutics Inc pay dividends?
Collapse

No, Voyager Therapeutics Inc doesn't pay dividends.

What is Voyager Therapeutics Inc 52 week high?
Collapse

Voyager Therapeutics Inc 52 week high is $5.55.

What is Voyager Therapeutics Inc 52 week low?
Collapse

Voyager Therapeutics Inc 52 week low is $2.65.

What is the 200-day moving average of Voyager Therapeutics Inc?
Collapse

Voyager Therapeutics Inc 200-day moving average is $4.04.

Who is Voyager Therapeutics Inc CEO?
Collapse

The CEO of Voyager Therapeutics Inc is Dr. Alfred W. Sandrock Jr., M.D., Ph.D..

How many employees Voyager Therapeutics Inc has?
Collapse

Voyager Therapeutics Inc has 141 employees.

What is the market cap of Voyager Therapeutics Inc?
Collapse

The market cap of Voyager Therapeutics Inc is $239M.

What is the P/E of Voyager Therapeutics Inc?
Collapse

The current P/E of Voyager Therapeutics Inc is null.

What is the EPS of Voyager Therapeutics Inc?
Collapse

The EPS of Voyager Therapeutics Inc is -$2.04.

What is the PEG Ratio of Voyager Therapeutics Inc?
Collapse

The PEG Ratio of Voyager Therapeutics Inc is 0.

What do analysts say about Voyager Therapeutics Inc?
Collapse

According to the analysts Voyager Therapeutics Inc is considered a buy.